Nico Van de Veire

Dr. Nico Van de Veire

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

14 October 2014
Verified
Book Chapter
Closed access
PDF file
NVNico Van de Veire
Nico Van de Veire

Verified
Journal Article
Open access
PDF file
EGEva van der Geest
Eva van der Geest
Nina Ajmone MarsanNina Ajmone Marsan
Nina Ajmone Marsan
DLDorien Laenens
Dorien Laenens
PDPhilippe Debonnaire
Philippe Debonnaire
MCMathias Claeys
Mathias Claeys
MRM.V. Veronique Regeer
M.V. Veronique Regeer
Background: Conventional HF treatment in transthyretin cardiac amyloidosis (ATTR-CA) resulting in restrictive cardiomyopathy is debated due to absent trial evidence in this specific sub-population of heart failure (HF) patients. Current European Society of Cardiology guidelines recommend the use of diuretics and mineralocorticoid receptor antagonists (MRAs). However, beta-blockers (BBs) and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARBs) are often discontinued due to hypotension or bradycardia. This study assesses real-world HF treatment patterns and their impact on survival in a multinational ATTR-CA cohort. Methods: A retrospective analysis of 794 ATTR-CA patients examined baseline BB, ACEi/ARB, and MRA prescriptions. The cohort was divided based on guideline publication dates. Results: Patients were predominantly male (73.2%) with a median age of 78 years. Prescription of diuretics (52.8%) and disease-modifying therapy (44.9%), mostly tafamidis, was common. BBs (43.7%) and ACEi/ARBs (41.2%) were prescribed more often in patients with higher NYHA class, elevated NT-proBNP, and more comorbidities. Blood pressure and heart rate were similar regardless of BB or ACEi/ARB use. BB prescription and combination therapy with BB and ACEi/ARB increased over time. Neither BB nor ACEi/ARB use significantly impacted mortality when analyzed in a multivariate Cox proportional hazard regression. Conclusions: Use of BBs and ACEi/ARBs has increased over time, particularly in advanced-stage ATTR-CA patients, and although these therapies appear to be reasonably tolerated, survival was not significantly altered.

14 September 2011 in European Heart Journal
Verified
Journal Article
Open access
PDF file
NVNico Van de Veire
Nico Van de Veire
JDJan Dierick
Jan Dierick
JSJohan De Sutter
Johan De Sutter
A 74-year-old patient presented at the Emergency Room with exercise-induced shortness of breath. Clinical examination revealed arterial hypertension (167/110 mmHg), decreased breathing sounds, and bilateral oedema. Electrocardiogram showed low voltage (Panel A) and aspecific repolarization changes. Chest X-ray confirmed bilateral pleural effusion. D-dimers (7644 ng/mL) and NTproBNP (9650 pg/mL) were elevated. Transthoracic echocardiograpy demonstrated a concentric hypertrophic left ventricle with myocardial sparkling, poor systolic function (ejection fraction 28%), dilated left atrium, and restrictive filling pattern. A large thrombus was seen in the left atrium (Panel B) and left ventricle (Panel C). Transoesophageal echocardiography demonstrated a left atrial thrombus passing through a patent foramen ovale (Panel D) and thrombotic material in the right atrium (Panel E) originating from the inferior caval vein. Deep venous thrombosis was confirmed in the superficial femoral vein. Angio-CT did not show pulmonary embolism. The patient was immobilized and treated with low-molecular-weight heparin. Four days later, left-sided thrombi had disappeared. Cereberal MRI demonstrated recent parieto-occipital infarction without neurological symptoms. Laboratory diagnosis of cardiac AL amyloidosis was suggested by elevated serum-free light chains: λ, 181 mg/L (ref: 5.7–26.3); κ, 20.3 mg/L (ref: 3.3–19.4); ratio: 0.11 (ref: 0.26–1.65), suspicion of clonal lambda fraction on serum immunofixation, monoclonal free lambda chains on urine immunofixation and urine lambda secretion: 16.4 mg/dL (ref: 0–1). Bone marrow showed a small clone of abnormal plasmacells (3%) (Panel F). Flow cytometry could confirm the abnormal clone (lambda) plasma cells. Characteristics of multiple myeloma such as hypercalcemia, bone pain, or lytic bone lesions were not present. Subsequently, coronary angiography was performed and myocardial right ventricular biopsy performed. There was non-obstructive coronary artery disease. Histological diagnosis of primary (AL) amyloidosis was confirmed on the congo red stain. Treatment was initiated with oral anticoagulants, thalidomide, and dexamethasone; serum-free lambda levels diminished subsequently.

18 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
EGEva van der Geest
Eva van der Geest
Nina Ajmone MarsanNina Ajmone Marsan
Nina Ajmone Marsan
DLD. Laenens
D. Laenens
PDPhilippe Debonnaire
Philippe Debonnaire
MCM. Claeys
M. Claeys
MRM.V. Veronique Regeer
M.V. Veronique Regeer
Background: Transthyretin cardiac amyloidosis (ATTR-CA) results from misfolded transthyretin protein deposition in the myocardium, causing restrictive cardiomyopathy, heart failure (HF), and conduction disorders. Conventional HF treatment in ATTR-CA is debated due to absent trial evidence. Current European Society of Cardiology guidelines recommend the use of diuretics and mineralocorticoid receptor antagonists (MRAs). However, beta-blockers (BBs) and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARBs) are often discontinued due to hypotension or bradycardia. This study assesses real-world HF treatment patterns and their impact on survival in a multinational ATTR-CA cohort. Methods: A retrospective analysis of 794 ATTR-CA patients examined baseline BB, ACEi/ARB, and MRA prescriptions. The cohort was divided based on guideline publication dates. Results: Patients were predominantly male (73.2%) with a median age of 78 years old. Prescription of diuretics (52.8%) and disease-modifying therapy (44.9%), mostly tafamidis, were common. BBs (43.7%) and ACEi/ARBs (41.2%) were prescribed more often in patients with higher NYHA class, elevated NT-proBNP, and more comorbidities. Blood pressure and heart rate were similar regardless of BB or ACEi/ARB use. BB prescription and combination therapy with BB and ACEi/ARB increased over time. Neither BB nor ACEi/ARB use significantly impacted mortality when analyzed in a multivariate Cox proportional hazard regression. Conclusions: BBs and ACEi/ARBs are more frequently used over time in particular in advanced-stage ATTR-CA patients and although BB and ACEi/ARB appear to be reasonably tolerated in the ones that were prescribed these drugs, survival was not significantly altered.